Literature DB >> 24295952

A practical fluorometric assay method to measure lysosomal acid lipase activity in dried blood spots for the screening of cholesteryl ester storage disease and Wolman disease.

Takenori Dairaku1, Takeo Iwamoto2, Minami Nishimura1, Masahiro Endo1, Toya Ohashi3, Yoshikatu Eto4.   

Abstract

Fluorometric measurements of 4-methylumbelliferone (4-MU) are generally used to screen lysosomal storage diseases (LSDs) using dried blood spots (DBSs). However, in DBS, it is difficult to measure lysosomal acid lipase (LAL) activity due to the influence of other lipases in whole blood. Recently, Hamilton used a fluorometric enzyme assay with 4-MU derivatives to measure the LAL activity in DBS. This method requires mercury chloride as stopping reagent, and the fluorescence intensity of 4-MU was measured at an acidic pH. We report a revised method to measure the LAL activity without using toxic mercury chloride and to measure the fluorescence intensity of 4-MU at a basic pH. For this measurement, we established a more practical method that does not require mercury chloride. The LAL activity in DBS was measured in 51 normal controls, seven obligate carriers and seven patients with CESD. The average LAL activities ± SD in the DBS from the normal, obligate carriers and CESD patients were 0.68 ± 0.2 (range: 0.3-1.08), 0.21 ± 0.1 (range: 0.11-0.41) and 0.02 ± 0.02 (range: 0-0.06) nmol/punch/h, respectively. There was a significant difference between the normal and the CESD. Our method does not require toxic mercury chloride and is an appropriate revised enzyme assay using DBS for screening patients with CESD.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  4-MU; 4-MUP; 4-Methylumbelliferone; 4-methylumbelliferone; 4-methylumbelliferyl-palmitate; CESD; Cholesteryl ester storage disease; DBS; Excitation wavelength; FWHM; Full width at half maximum; LAL; LSD; Lysosomal acid lipase; WD; Wolman disease; cholesteryl ester storage disease; dried blood spots; full width at half maximum; lysosomal acid lipase; lysosomal storage disorders

Mesh:

Substances:

Year:  2013        PMID: 24295952     DOI: 10.1016/j.ymgme.2013.11.003

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  9 in total

Review 1.  The role of sebelipase alfa in the treatment of lysosomal acid lipase deficiency.

Authors:  Angelika L Erwin
Journal:  Therap Adv Gastroenterol       Date:  2017-04-26       Impact factor: 4.409

2.  Loss of Mitochondrial Function Impairs Lysosomes.

Authors:  Julie Demers-Lamarche; Gérald Guillebaud; Mouna Tlili; Kiran Todkar; Noémie Bélanger; Martine Grondin; Angela P Nguyen; Jennifer Michel; Marc Germain
Journal:  J Biol Chem       Date:  2016-03-17       Impact factor: 5.157

3.  Cholesteryl ester storage disease of clinical and genetic characterisation: A case report and review of literature.

Authors:  Elias Badal Rashu; Anders Ellekær Junker; Karen Vagner Danielsen; Emilie Dahl; Ole Hamberg; Line Borgwardt; Vibeke Brix Christensen; Nicolai J Wewer Albrechtsen; Lise L Gluud
Journal:  World J Clin Cases       Date:  2020-05-06       Impact factor: 1.337

Review 4.  Regulation of lysosomal ion homeostasis by channels and transporters.

Authors:  Jian Xiong; Michael X Zhu
Journal:  Sci China Life Sci       Date:  2016-07-19       Impact factor: 6.038

Review 5.  Targeting Wolman Disease and Cholesteryl Ester Storage Disease: Disease Pathogenesis and Therapeutic Development.

Authors:  Francis Aguisanda; Natasha Thorne; Wei Zheng
Journal:  Curr Chem Genom Transl Med       Date:  2017-01-30

6.  A fast, miniaturised in-vitro assay developed for quantification of lipase enzyme activity.

Authors:  Ariane Menden; Davane Hall; Daniel Paris; Venkatarian Mathura; Fiona Crawford; Michael Mullan; Stefan Crynen; Ghania Ait-Ghezala
Journal:  J Enzyme Inhib Med Chem       Date:  2019-12       Impact factor: 5.051

7.  A kinetic assay of total lipase activity for detecting lysosomal acid lipase deficiency (LAL-D) and the molecular characterization of 18 LAL-D patients from Russia.

Authors:  Nikolay Mayanskiy; Ekaterina Brzhozovskaya; Alexander Pushkov; Tatiana Strokova; Nikolay Vlasov; Andrej Surkov; Olga Gundobina; Kirill Savostianov
Journal:  JIMD Rep       Date:  2019-06-03

8.  Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress.

Authors:  Xihui Liu; Suryavathi Viswanadhapalli; Shourya Kumar; Tae-Kyung Lee; Andrew Moore; Shihong Ma; Liping Chen; Michael Hsieh; Mengxing Li; Gangadhara R Sareddy; Karla Parra; Eliot B Blatt; Tanner C Reese; Yuting Zhao; Annabel Chang; Hui Yan; Zhenming Xu; Uday P Pratap; Zexuan Liu; Carlos M Roggero; Zhenqiu Tan; Susan T Weintraub; Yan Peng; Rajeshwar R Tekmal; Carlos L Arteaga; Jennifer Lippincott-Schwartz; Ratna K Vadlamudi; Jung-Mo Ahn; Ganesh V Raj
Journal:  Nat Cancer       Date:  2022-06-02

9.  Therapeutic efficacy of rscAAVrh74.miniCMV.LIPA gene therapy in a mouse model of lysosomal acid lipase deficiency.

Authors:  Patricia Lam; Anna Ashbrook; Deborah A Zygmunt; Cong Yan; Hong Du; Paul T Martin
Journal:  Mol Ther Methods Clin Dev       Date:  2022-08-04       Impact factor: 5.849

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.